{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T22:36:03Z","timestamp":1792103763731,"version":"4.4.0"},"reference-count":125,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,13]],"date-time":"2024-02-13T00:00:00Z","timestamp":1707782400000},"content-version":"vor","delay-in-days":43,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2024]]},"DOI":"10.1016\/j.ctarc.2024.100796","type":"journal-article","created":{"date-parts":[[2024,2,14]],"date-time":"2024-02-14T14:05:55Z","timestamp":1707919555000},"page":"100796","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Exploring vismodegib: A non-surgical breakthrough in the management of advanced periocular basal cell carcinoma"],"prefix":"10.1016","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3973-7838","authenticated-orcid":false,"given":"Georgios","family":"Lavasidis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Argyrios","family":"Tzamalis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Tsinopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos","family":"Ziakas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctarc.2024.100796_bib0001","series-title":"Cancer Facts & Figures 2023","year":"2023"},{"issue":"9","key":"10.1016\/j.ctarc.2024.100796_bib0002","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1001\/jamadermatol.2015.1188","article-title":"Trends in basal cell carcinoma incidence and identification of high-risk subgroups, 1998-2012","volume":"151","author":"Asgari","year":"2015","journal-title":"JAMA Dermatol."},{"key":"10.1016\/j.ctarc.2024.100796_bib0003","doi-asserted-by":"crossref","unstructured":"SEER [Internet]. [cited 2024 Feb 7]. Surveillance, Epidemiology, and End Results Program. Available from: https:\/\/seer.cancer.gov\/index.html.","DOI":"10.1093\/jncimonographs\/lgae033"},{"issue":"21","key":"10.1016\/j.ctarc.2024.100796_bib0004","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1056\/NEJMra044151","article-title":"Basal-cell carcinoma","volume":"353","author":"Rubin","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.ctarc.2024.100796_bib0005","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/jid.2013.304","article-title":"Non-melanoma skin cancer incidence and impact of skin cancer screening on incidence","volume":"134","author":"Eisemann","year":"2014","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.ctarc.2024.100796_bib0006","series-title":"Non-melanoma Skin Cancer Incidence Statistics","year":"2018"},{"issue":"5","key":"10.1016\/j.ctarc.2024.100796_bib0007","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1111\/j.1365-2133.2012.10830.x","article-title":"A systematic review of worldwide incidence of nonmelanoma skin cancer","volume":"166","author":"Lomas","year":"2012","journal-title":"Br. J. Dermatol."},{"issue":"4","key":"10.1016\/j.ctarc.2024.100796_bib0008","doi-asserted-by":"crossref","first-page":"e307","DOI":"10.1111\/ijd.12273","article-title":"Clinico-epidemiological data on non-melanoma skin cancer in Greece: 5-year experience (2005-2009) in a tertiary referral center","volume":"53","author":"Katoulis","year":"2014","journal-title":"Int. J. Dermatol."},{"issue":"2","key":"10.1016\/j.ctarc.2024.100796_bib0009","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1001\/archderm.1995.01690140041006","article-title":"Sunlight exposure, pigmentary factors, and risk of nonmelanocytic skin cancer. I. Basal cell carcinoma","volume":"131","author":"Gallagher","year":"1995","journal-title":"Arch. Dermatol."},{"key":"10.1016\/j.ctarc.2024.100796_bib0010","series-title":"StatPearls [Internet]","article-title":"Basal Cell Carcinoma","author":"McDaniel","year":"2024"},{"issue":"6","key":"10.1016\/j.ctarc.2024.100796_bib0011","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1093\/aje\/kwt073","article-title":"Basal-cell carcinoma incidence and associated risk factors in U.S. women and men","volume":"178","author":"Wu","year":"2013","journal-title":"Am. J. Epidemiol."},{"issue":"1","key":"10.1016\/j.ctarc.2024.100796_bib0012","doi-asserted-by":"crossref","first-page":"420","DOI":"10.4081\/oncol.2020.420","article-title":"Periocular basal cell carcinoma - clinical perspectives","volume":"14","author":"Furdova","year":"2020","journal-title":"Oncol. Rev."},{"key":"10.1016\/j.ctarc.2024.100796_bib0013","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/8304271","article-title":"Male sex is an inherent risk factor for basal cell carcinoma","volume":"2019","author":"Bassukas","year":"2019","journal-title":"J. Skin. Cancer"},{"issue":"3","key":"10.1016\/j.ctarc.2024.100796_bib0014","first-page":"219","article-title":"A five-year retrospective analysis of basal cell carcinoma: a monocentric study","volume":"35","author":"Ozkanli","year":"2020","journal-title":"Medeni. Med. J."},{"issue":"6 Pt 1","key":"10.1016\/j.ctarc.2024.100796_bib0015","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/0190-9622(90)70344-H","article-title":"Histologic pattern analysis of basal cell carcinoma. Study of a series of 1039 consecutive neoplasms","volume":"23","author":"Sexton","year":"1990","journal-title":"J. Am. Acad. Dermatol."},{"issue":"8","key":"10.1016\/j.ctarc.2024.100796_bib0016","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1001\/archderm.138.8.1043","article-title":"Predictors of extensive subclinical spread in nonmelanoma skin cancer treated with Mohs micrographic surgery","volume":"138","author":"Batra","year":"2002","journal-title":"Arch. Dermatol."},{"issue":"7418","key":"10.1016\/j.ctarc.2024.100796_bib0017","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1136\/bmj.327.7418.794","article-title":"Basal cell carcinoma","volume":"327","author":"Wong","year":"2003","journal-title":"BMJ"},{"issue":"12","key":"10.1016\/j.ctarc.2024.100796_bib0018","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1111\/ans.17030","article-title":"The anatomical distribution of non-melanoma skin cancer: a retrospective cohort study of 22\u2009303 Australian cases","volume":"91","author":"Khalid","year":"2021","journal-title":"ANZ. J. Surg."},{"issue":"2 Pt 2","key":"10.1016\/j.ctarc.2024.100796_bib0019","first-page":"257","article-title":"Basal cell carcinoma on the eyelids: own experience","volume":"30","author":"Salomon","year":"2004","journal-title":"Dermatol. Surg."},{"key":"10.1016\/j.ctarc.2024.100796_bib0020","series-title":"Chapter 2: Eyelids. In: Kanski's Clinical Ophthalmology","first-page":"50","author":"Salmon","year":"2019"},{"issue":"8","key":"10.1016\/j.ctarc.2024.100796_bib0021","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1111\/ijd.12089","article-title":"Malignancies of the eyelid: a review of primary and metastatic cancers","volume":"52","author":"Dekmezian","year":"2013","journal-title":"Int. J. Dermatol."},{"issue":"2","key":"10.1016\/j.ctarc.2024.100796_bib0022","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/0039-6257(93)90100-L","article-title":"Basal cell carcinoma of the eyelid and periocular skin","volume":"38","author":"Margo","year":"1993","journal-title":"Surv. Ophthalmol."},{"issue":"1","key":"10.1016\/j.ctarc.2024.100796_bib0023","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s10792-016-0258-8","article-title":"Retrospective clinicopathological study of 129 cancerous and 18 precancerous lesions of the eyelids in North-Western Greece","volume":"37","author":"Tzoutzos","year":"2017","journal-title":"Int. Ophthalmol."},{"issue":"1","key":"10.1016\/j.ctarc.2024.100796_bib0024","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1186\/s12886-022-02494-9","article-title":"Periocular basal cell carcinoma results and surgical outcome during a 5-year period in a larger Danish population","volume":"22","author":"Karlsd\u00f3ttir","year":"2022","journal-title":"BMC. Ophthalmol."},{"issue":"2","key":"10.1016\/j.ctarc.2024.100796_bib0025","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.ajo.2011.08.004","article-title":"Risk factors for orbital exenteration in periocular Basal cell carcinoma","volume":"153","author":"Iuliano","year":"2012","journal-title":"Am. J. Ophthalmol."},{"issue":"22","key":"10.1016\/j.ctarc.2024.100796_bib0026","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.2217\/fon.15.190","article-title":"Management of periorbital basal cell carcinoma with orbital invasion","volume":"11","author":"Sun","year":"2015","journal-title":"Future Oncol."},{"issue":"1","key":"10.1016\/j.ctarc.2024.100796_bib0027","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1097\/IOP.0000000000001133","article-title":"Change in eyelid carcinoma t category with use of the 8th versus 7th edition of the American joint committee on cancer: cancer staging manual","volume":"35","author":"Ding","year":"2019","journal-title":"Ophthalmic Plast. Reconstr. Surg."},{"issue":"11","key":"10.1016\/j.ctarc.2024.100796_bib0028","article-title":"Interventions for basal cell carcinoma of the skin","volume":"11","author":"Thomson","year":"2020","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.ctarc.2024.100796_bib0029","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.2147\/OTT.S130371","article-title":"Ocular basal cell carcinoma: a brief literature review of clinical diagnosis and treatment","volume":"10","author":"Shi","year":"2017","journal-title":"Onco Targets. Ther."},{"issue":"1","key":"10.1016\/j.ctarc.2024.100796_bib0030","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1097\/IIO.0000000000000149","article-title":"Review of targeted therapies for periocular tumors","volume":"57","author":"Mehta","year":"2017","journal-title":"Int. Ophthalmol. Clin."},{"issue":"3","key":"10.1016\/j.ctarc.2024.100796_bib0031","doi-asserted-by":"crossref","first-page":"232","DOI":"10.3109\/09546634.2012.690506","article-title":"Management of periocular basal cell carcinoma by Mohs micrographic surgery","volume":"24","author":"Litwin","year":"2013","journal-title":"J. Dermatolog. Treat."},{"issue":"8","key":"10.1016\/j.ctarc.2024.100796_bib0032","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1111\/aos.12441","article-title":"Cryosurgery of eyelid basal cell carcinomas including 781 cases treated over 30 years","volume":"92","author":"Lindgren","year":"2014","journal-title":"Acta Ophthalmol."},{"issue":"10","key":"10.1016\/j.ctarc.2024.100796_bib0033","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1038\/sj.eye.6702380","article-title":"Orbital exenteration for invasive skin tumours","volume":"20","author":"Tyers","year":"2006","journal-title":"Eye (Lond)"},{"issue":"3","key":"10.1016\/j.ctarc.2024.100796_bib0034","first-page":"442","article-title":"Basal cell carcinoma associated with orbital invasion: clinical features and treatment options","volume":"32","author":"Meads","year":"2006","journal-title":"Dermatol. Surg."},{"issue":"9","key":"10.1016\/j.ctarc.2024.100796_bib0035","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1111\/j.1468-3083.2009.03195.x","article-title":"Photodynamic therapy of eyelid basal cell carcinoma","volume":"23","author":"Kotim\u00e4ki","year":"2009","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"issue":"4","key":"10.1016\/j.ctarc.2024.100796_bib0036","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1177\/11206721211035614","article-title":"Long-term efficacy and safety of imiquimod 5% and fluorouracil 1% creams in medical monotherapy of complex eyelid basal cell carcinomas","volume":"32","author":"Singh","year":"2022","journal-title":"Eur. J. Ophthalmol."},{"issue":"8","key":"10.1016\/j.ctarc.2024.100796_bib0037","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1007\/s00417-007-0561-1","article-title":"Treatment of basal cell carcinoma of the eyelids with 5% topical imiquimod: a 3-year follow-up study","volume":"245","author":"Choontanom","year":"2007","journal-title":"Graefes. Arch. Clin. Exp. Ophthalmol."},{"issue":"9","key":"10.1016\/j.ctarc.2024.100796_bib0038","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1158\/1078-0432.CCR-12-1956","article-title":"U.S. food and drug administration approval: vismodegib for recurrent, locally advanced, or metastatic basal cell carcinoma","volume":"19","author":"Axelson","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ctarc.2024.100796_bib0039","unstructured":"FDA Labeling Information \u2013 Erivedge [Internet]. US Food and Drug Administration; Available from: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/203388lbl.pdf."},{"issue":"2","key":"10.1016\/j.ctarc.2024.100796_bib0040","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1097\/IOP.0b013e3182831bf3","article-title":"Targeted therapy for orbital and periocular basal cell carcinoma and squamous cell carcinoma","volume":"29","author":"Yin","year":"2013","journal-title":"Ophthalmic Plast. Reconstr. Surg."},{"key":"10.1016\/j.ctarc.2024.100796_bib0041","unstructured":"European Public Assessment Report (EPAR) For Erivedge [Internet]. European Medicines Agency; Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/erivedge."},{"issue":"8","key":"10.1016\/j.ctarc.2024.100796_bib0042","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.molmed.2010.05.003","article-title":"Learning from Jekyll to control Hyde: hedgehog signaling in development and cancer","volume":"16","author":"Barakat","year":"2010","journal-title":"Trends. Mol. Med."},{"issue":"5","key":"10.1016\/j.ctarc.2024.100796_bib0043","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1517\/13543776.2015.1019864","article-title":"Hedgehog inhibitors: a patent review (2013 - present)","volume":"25","author":"Xin","year":"2015","journal-title":"Expert. Opin. Ther. Pat."},{"issue":"6","key":"10.1016\/j.ctarc.2024.100796_bib0044","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/nrd3753","article-title":"Vismodegib","volume":"11","author":"Dlugosz","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"issue":"2","key":"10.1016\/j.ctarc.2024.100796_bib0045","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1177\/107327481602300207","article-title":"Role of vismodegib in the management of advanced periocular basal cell carcinoma","volume":"23","author":"Cox","year":"2016","journal-title":"Cancer Control"},{"issue":"7","key":"10.1016\/j.ctarc.2024.100796_bib0046","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/nrc3079","article-title":"The Hedgehog's tale: developing strategies for targeting cancer","volume":"11","author":"Ng","year":"2011","journal-title":"Nat. Rev. Cancer"},{"issue":"8","key":"10.1016\/j.ctarc.2024.100796_bib0047","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1517\/17460441.2014.920816","article-title":"Discovery and preclinical development of vismodegib","volume":"9","author":"Gould","year":"2014","journal-title":"Expert. Opin. Drug Discov."},{"issue":"23","key":"10.1016\/j.ctarc.2024.100796_bib0048","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1056\/NEJMoa1113713","article-title":"Efficacy and safety of vismodegib in advanced basal-cell carcinoma","volume":"366","author":"Sekulic","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.ctarc.2024.100796_bib0049","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/s41433-021-01493-2","article-title":"Vismodegib improves quality of life in patients with periocular locally advanced basal cell carcinoma: subgroup analysis, STEVIE trial","volume":"36","author":"Gershoni","year":"2022","journal-title":"Eye (Lond)"},{"issue":"7","key":"10.1016\/j.ctarc.2024.100796_bib0050","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1001\/jamaophthalmol.2020.1539","article-title":"Outcomes of vismodegib for periocular locally advanced basal cell carcinoma from an open-label trial","volume":"138","author":"Ben Ishai","year":"2020","journal-title":"JAMa Ophthalmol."},{"issue":"23","key":"10.1016\/j.ctarc.2024.100796_bib0051","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1056\/NEJMoa1113538","article-title":"Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome","volume":"366","author":"Tang","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.ctarc.2024.100796_bib0052","doi-asserted-by":"crossref","first-page":"537","DOI":"10.6004\/jnccn.2017.0051","article-title":"Implementation of systemic hedgehog inhibitors in daily practice as neoadjuvant therapy","volume":"15","author":"Tang","year":"2017","journal-title":"J. Natl. Compr. Canc. Netw."},{"issue":"5","key":"10.1016\/j.ctarc.2024.100796_bib0053","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.ad.2022.01.005","article-title":"Vismodegib and sonidegib in locally advanced and metastatic basal cell carcinoma: update on hedgehog pathway inhibitors","volume":"113","author":"Kurnia Wijaya","year":"2022","journal-title":"Actas. Dermosifiliogr."},{"issue":"2","key":"10.1016\/j.ctarc.2024.100796_bib0054","doi-asserted-by":"crossref","first-page":"156","DOI":"10.36849\/JDD.5657","article-title":"A review of hedgehog inhibitors sonidegib and vismodegib for treatment of advanced basal cell carcinoma","volume":"20","author":"Migden","year":"2021","journal-title":"J. Drugs Dermatol."},{"key":"10.1016\/j.ctarc.2024.100796_bib0055","unstructured":"FDA Labeling Information \u2013 Odomzo [Internet]. US Food and Drug Administration; Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/205266s002lbl.pdf."},{"key":"10.1016\/j.ctarc.2024.100796_bib0056","unstructured":"European Public Assessment Report (EPAR) For Odomzo [Internet]. European Medicines Agency; Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/odomzo."},{"issue":"3","key":"10.1016\/j.ctarc.2024.100796_bib0057","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s40257-023-00763-x","article-title":"Efficacy and safety of sonic hedgehog inhibitors in basal cell carcinomas: an updated systematic review and meta-analysis (2009-2022)","volume":"24","author":"Nguyen","year":"2023","journal-title":"Am. J. Clin. Dermatol."},{"issue":"6","key":"10.1016\/j.ctarc.2024.100796_bib0058","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1080\/14656566.2022.2050215","article-title":"Topical hedgehog inhibitors for basal cell carcinoma: how far away are we?","volume":"23","author":"Zhu","year":"2022","journal-title":"Expert. Opin. PharmacOther."},{"issue":"19","key":"10.1016\/j.ctarc.2024.100796_bib0059","doi-asserted-by":"crossref","first-page":"10725","DOI":"10.3390\/ijms221910725","article-title":"Patidegib in dermatology: a current review","volume":"22","author":"Cosio","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ctarc.2024.100796_bib0060","doi-asserted-by":"crossref","DOI":"10.1002\/lsm.23766","article-title":"Laser-assisted topical delivery of vismodegib reduces hedgehog gene expression in human basal cell carcinomas in vivo","author":"Olesen","year":"2024","journal-title":"Lasers. Surg. Med."},{"issue":"11","key":"10.1016\/j.ctarc.2024.100796_bib0061","doi-asserted-by":"crossref","first-page":"2778","DOI":"10.3390\/cancers14112778","article-title":"Basal cell carcinoma: pathology, current clinical treatment, and potential use of lipid nanoparticles","volume":"14","author":"\u0141asi\u0144ska","year":"2022","journal-title":"Cancers. (Basel)"},{"issue":"1","key":"10.1016\/j.ctarc.2024.100796_bib0062","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1186\/s12889-023-15958-4","article-title":"Human and environmental impacts of nanoparticles: a scoping review of the current literature","volume":"23","author":"Kumah","year":"2023","journal-title":"BMC. Public Health"},{"issue":"1","key":"10.1016\/j.ctarc.2024.100796_bib0063","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s12302-018-0132-6","article-title":"Nanoparticles in the environment: where do we come from, where do we go to?","volume":"30","author":"Bundschuh","year":"2018","journal-title":"Environ. Sci. Eur."},{"issue":"10","key":"10.1016\/j.ctarc.2024.100796_bib0064","doi-asserted-by":"crossref","first-page":"4239","DOI":"10.1007\/s11164-023-05099-z","article-title":"Batch to continuous photocatalytic degradation of phenol using nitrogen-rich g-C3N4 nanocomposites","volume":"49","author":"Al-Nayili","year":"2023","journal-title":"Res. Chem. Intermed."},{"key":"10.1016\/j.ctarc.2024.100796_bib0065","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.ctarc.2024.100796_bib0066","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1136\/bmjebm-2017-110853","article-title":"Methodological quality and synthesis of case series and case reports","volume":"23","author":"Murad","year":"2018","journal-title":"BMJ Evid. Based Med."},{"issue":"6","key":"10.1016\/j.ctarc.2024.100796_bib0067","doi-asserted-by":"crossref","first-page":"e15172","DOI":"10.1111\/dth.15172","article-title":"Outcomes of adjunctive therapies post hedgehog inhibitors in the management of locally advanced basal cell carcinoma: a systematic review and pooled analysis","volume":"34","author":"Patel","year":"2021","journal-title":"Dermatol. Ther."},{"issue":"1","key":"10.1016\/j.ctarc.2024.100796_bib0068","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1186\/s12885-017-3286-5","article-title":"Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study","volume":"17","author":"Sekulic","year":"2017","journal-title":"BMC. Cancer"},{"key":"10.1016\/j.ctarc.2024.100796_bib0069","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2021.100844","article-title":"Vismodegib in neoadjuvant treatment of locally advanced basal cell carcinoma: first results of a multicenter, open-label, phase 2 trial (VISMONEO study): neoadjuvant Vismodegib in Locally Advanced Basal Cell Carcinoma","volume":"35","author":"Bertrand","year":"2021","journal-title":"EClinicalMedicine"},{"issue":"2","key":"10.1016\/j.ctarc.2024.100796_bib0070","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"issue":"4","key":"10.1016\/j.ctarc.2024.100796_bib0071","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1097\/IOP.0000000000002328","article-title":"Recurrence following globe sparing excision for basal cell carcinoma with anterior orbital invasion","volume":"39","author":"Tong","year":"2023","journal-title":"Ophthalmic Plast. Reconstr. Surg."},{"issue":"3","key":"10.1016\/j.ctarc.2024.100796_bib0072","first-page":"9240","article-title":"Treatment of periocular advanced basal cell carcinoma with Hedgehog pathway inhibitors: a single-center study and a new dedicated therapeutic protocol","volume":"13","author":"De Giorgi","year":"2021","journal-title":"Dermatol. Reports"},{"issue":"6","key":"10.1016\/j.ctarc.2024.100796_bib0073","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.abd.2021.04.012","article-title":"Vismodegib for treatment of periocular basal cell carcinoma - 6-year experience from a tertiary cancer center","volume":"96","author":"Xavier","year":"2021","journal-title":"An. Bras. Dermatol."},{"issue":"7","key":"10.1016\/j.ctarc.2024.100796_bib0074","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1097\/DSS.0000000000002924","article-title":"Hepatotoxicity associated with vismodegib: could dose reduction be an effective management?","volume":"47","author":"de Perosanz-Lobo","year":"2021","journal-title":"Dermatol. Surg."},{"issue":"7","key":"10.1016\/j.ctarc.2024.100796_bib0075","doi-asserted-by":"crossref","first-page":"e1240","DOI":"10.1002\/onco.13820","article-title":"Vismodegib for preservation of visual function in patients with advanced periocular basal cell carcinoma: the VISORB trial","volume":"26","author":"Kahana","year":"2021","journal-title":"Oncologist"},{"issue":"5","key":"10.1016\/j.ctarc.2024.100796_bib0076","first-page":"552","article-title":"Vismodegib as eye-sparing neoadjuvant treatment for locally advanced periocular basal cell carcinoma","volume":"20","author":"Angnardo","year":"2021","journal-title":"J. Drugs Dermatol."},{"issue":"10","key":"10.1016\/j.ctarc.2024.100796_bib0077","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1038\/s41433-020-01291-2","article-title":"Neoadjuvant vismodegib in the management of locally advanced periocular basal cell carcinoma","volume":"35","author":"Curragh","year":"2021","journal-title":"Eye (Lond)"},{"issue":"Suppl 1","key":"10.1016\/j.ctarc.2024.100796_bib0078","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s00105-020-04626-y","article-title":"[Vismodegib therapy for a large basal cell carcinoma on the midface with orbital involvement]","volume":"71","author":"Nasifoglu","year":"2020","journal-title":"Hautarzt"},{"issue":"6","key":"10.1016\/j.ctarc.2024.100796_bib0079","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1080\/01676830.2020.1803364","article-title":"Basal cell carcinoma with extensive periorbital involvement response to vismodegib","volume":"40","author":"Shoji","year":"2021","journal-title":"Orbit"},{"key":"10.1016\/j.ctarc.2024.100796_bib0080","article-title":"Treatment of periocular basal cell carcinoma with neoadjuvant vismodegib","volume":"19","author":"Su","year":"2020","journal-title":"Am. J. Ophthalmol. Case Rep."},{"issue":"1","key":"10.1016\/j.ctarc.2024.100796_bib0081","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1080\/09546634.2020.1771262","article-title":"The effectiveness of vismodegib in patients with advanced periocular basal cell carcinoma: a case series of 13 patients","volume":"33","author":"Villani","year":"2022","journal-title":"J. Dermatolog. Treat."},{"issue":"2","key":"10.1016\/j.ctarc.2024.100796_bib0082","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1080\/01676830.2020.1753783","article-title":"Orbito-scleral-sinus invasion of basal cell carcinoma in an immunocompromised patient on vismodegib","volume":"40","author":"Tran","year":"2021","journal-title":"Orbit"},{"issue":"9","key":"10.1016\/j.ctarc.2024.100796_bib0083","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/j.ijom.2020.03.006","article-title":"Complete remission of advanced, locally invasive basal cell carcinoma with vismodegib","volume":"49","author":"Glen","year":"2020","journal-title":"Int. J. Oral Maxillofac. Surg."},{"issue":"11","key":"10.1016\/j.ctarc.2024.100796_bib0084","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1038\/s41433-020-0778-3","article-title":"Vismodegib for periocular basal cell carcinoma: an international multicentre case series","volume":"34","author":"Oliphant","year":"2020","journal-title":"Eye (Lond)"},{"issue":"10","key":"10.1016\/j.ctarc.2024.100796_bib0085","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.ad.2018.05.022","article-title":"Aggressive inferior eyelid basal cell carcinoma: advantage of neoadjuvant vismodegib","volume":"110","author":"Monteiro","year":"2019","journal-title":"Actas. Dermosifiliogr. (Engl. Ed)"},{"key":"10.1016\/j.ctarc.2024.100796_bib0086","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ajo.2019.04.013","article-title":"Efficacy of vismodegib for the treatment of orbital and advanced periocular basal cell carcinoma","volume":"207","author":"Eiger-Moscovich","year":"2019","journal-title":"Am. J. Ophthalmol."},{"issue":"1","key":"10.1016\/j.ctarc.2024.100796_bib0087","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1097\/IOP.0000000000001166","article-title":"Neoadjuvant vismodegib and mohs micrographic surgery for locally advanced periocular basal cell carcinoma","volume":"35","author":"Gonz\u00e1lez","year":"2019","journal-title":"Ophthalmic Plast. Reconstr. Surg."},{"issue":"6","key":"10.1016\/j.ctarc.2024.100796_bib0088","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1136\/bjophthalmol-2018-312277","article-title":"Ocular preservation with neoadjuvant vismodegib in patients with locally advanced periocular basal cell carcinoma","volume":"103","author":"Sagiv","year":"2019","journal-title":"Br. J. Ophthalmol."},{"issue":"3","key":"10.1016\/j.ctarc.2024.100796_bib0089","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s00347-018-0734-9","article-title":"[Advanced periocular basal cell carcinoma-a therapeutic challenge]","volume":"116","author":"Lauterbach","year":"2019","journal-title":"Ophthalmologe"},{"issue":"3","key":"10.1016\/j.ctarc.2024.100796_bib0090","doi-asserted-by":"crossref","first-page":"e394","DOI":"10.1097\/MJT.0000000000000721","article-title":"Switching the smoothened inhibitor may have benefit in advanced basal cell carcinoma","volume":"25","author":"Khalid","year":"2018","journal-title":"Am. J. Ther."},{"issue":"7","key":"10.1016\/j.ctarc.2024.100796_bib0091","doi-asserted-by":"crossref","first-page":"e1424","DOI":"10.1097\/GOX.0000000000001424","article-title":"Vismodegib for locally advanced periocular and orbital basal cell carcinoma: a review of 15 consecutive cases","volume":"5","author":"Wong","year":"2017","journal-title":"Plast. Reconstr. Surg. Glob. Open"},{"issue":"1","key":"10.1016\/j.ctarc.2024.100796_bib0092","first-page":"64","article-title":"[Vismodegib therapy for periocular basal cell carcinoma]","volume":"234","author":"Keser\u00fc","year":"2017","journal-title":"Klin. Monbl. Augenheilkd"},{"key":"10.1016\/j.ctarc.2024.100796_bib0093","first-page":"D187","article-title":"[Vismodegib for basal cell carcinoma: targeted therapy in case of locally advanced or metastasised disease]","volume":"160","author":"Reinders","year":"2016","journal-title":"Ned. Tijdschr. Geneeskd."},{"issue":"3","key":"10.1016\/j.ctarc.2024.100796_bib0094","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1001\/jamaophthalmol.2015.3600","article-title":"Enlarging multiple neoplastic skin growths","volume":"134","author":"Feinstein","year":"2016","journal-title":"JAMa Ophthalmol."},{"issue":"3S Suppl 1","key":"10.1016\/j.ctarc.2024.100796_bib0095","doi-asserted-by":"crossref","first-page":"S68","DOI":"10.1097\/IOP.0000000000000565","article-title":"Secondary resistance to vismodegib after initial successful treatment of extensive recurrent periocular basal cell carcinoma with orbital invasion","volume":"33","author":"Papastefanou","year":"2017","journal-title":"Ophthalmic Plast. Reconstr. Surg."},{"issue":"2","key":"10.1016\/j.ctarc.2024.100796_bib0096","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.ajo.2015.04.040","article-title":"Hedgehog pathway inhibition for locally advanced periocular basal cell carcinoma and basal cell nevus syndrome","volume":"160","author":"Ozgur","year":"2015","journal-title":"Am. J. Ophthalmol."},{"issue":"9","key":"10.1016\/j.ctarc.2024.100796_bib0097","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1001\/jamadermatol.2015.0326","article-title":"Concurrent vismodegib and radiotherapy for recurrent, advanced basal cell carcinoma","volume":"151","author":"Pollom","year":"2015","journal-title":"JAMa Dermatol."},{"issue":"3","key":"10.1016\/j.ctarc.2024.100796_bib0098","first-page":"1777","article-title":"Treatment of multiple unresectable basal cell carcinomas from Gorlin\u2013Goltz syndrome: a case report","volume":"35","author":"Ojevwe","year":"2015","journal-title":"Anticancer Res."},{"issue":"6","key":"10.1016\/j.ctarc.2024.100796_bib0099","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/IOP.0000000000000388","article-title":"Efficacy of vismodegib (Erivedge) for basal cell carcinoma involving the orbit and periocular area","volume":"31","author":"Demirci","year":"2015","journal-title":"Ophthalmic Plast. Reconstr. Surg."},{"issue":"5","key":"10.1016\/j.ctarc.2024.100796_bib0100","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.jaad.2014.05.020","article-title":"An investigator-initiated open-label clinical trial of vismodegib as a neoadjuvant to surgery for high-risk basal cell carcinoma","volume":"71","author":"Ally","year":"2014","journal-title":"J. Am. Acad. Dermatol."},{"issue":"12","key":"10.1016\/j.ctarc.2024.100796_bib0101","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1001\/jamaophthalmol.2013.5018","article-title":"Vismodegib for periocular and orbital basal cell carcinoma","volume":"131","author":"Gill","year":"2013","journal-title":"JAMa Ophthalmol."},{"issue":"10","key":"10.1016\/j.ctarc.2024.100796_bib0102","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1001\/jamaophthalmol.2013.4430","article-title":"Vismodegib as eye-sparing adjuvant treatment for orbital basal cell carcinoma","volume":"131","author":"Kahana","year":"2013","journal-title":"JAMa Ophthalmol."},{"issue":"11","key":"10.1016\/j.ctarc.2024.100796_bib0103","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1111\/dsu.12281","article-title":"Histologic changes in basal cell carcinoma after treatment with vismodegib","volume":"39","author":"Aldabagh","year":"2013","journal-title":"Dermatol. Surg."},{"issue":"2","key":"10.1016\/j.ctarc.2024.100796_bib0104","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1001\/jamadermatol.2013.1798","article-title":"New onset of keratoacanthomas after vismodegib treatment for locally advanced basal cell carcinomas: a report of 2 cases","volume":"149","author":"Aasi","year":"2013","journal-title":"JAMa Dermatol."},{"key":"10.1016\/j.ctarc.2024.100796_bib0105","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.ejca.2017.08.022","article-title":"Vismodegib in patients with advanced basal cell carcinoma: primary analysis of STEVIE, an international, open-label trial","volume":"86","author":"Basset-S\u00e9guin","year":"2017","journal-title":"Eur. J. Cancer"},{"issue":"2","key":"10.1016\/j.ctarc.2024.100796_bib0106","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.det.2011.11.003","article-title":"The Skindex instruments to measure the effects of skin disease on quality of life","volume":"30","author":"Chren","year":"2012","journal-title":"Dermatol. Clin."},{"key":"10.1016\/j.ctarc.2024.100796_bib0107","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jdcr.2022.07.032","article-title":"Metastatic same-site squamous cell carcinoma arising during vismodegib therapy for basal cell carcinoma","volume":"28","author":"Zhao","year":"2022","journal-title":"JAAD. Case Rep."},{"issue":"5","key":"10.1016\/j.ctarc.2024.100796_bib0108","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1111\/jdv.12526","article-title":"Development of squamous cell carcinoma into basal cell carcinoma under treatment with Vismodegib","volume":"29","author":"Saintes","year":"2015","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"issue":"1","key":"10.1016\/j.ctarc.2024.100796_bib0109","doi-asserted-by":"crossref","first-page":"e33","DOI":"10.1016\/j.jaad.2013.01.023","article-title":"Emergence of a squamous cell carcinoma phenotype following treatment of metastatic basal cell carcinoma with vismodegib","volume":"69","author":"Iarrobino","year":"2013","journal-title":"J. Am. Acad. Dermatol."},{"issue":"6","key":"10.1016\/j.ctarc.2024.100796_bib0110","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.jaad.2015.03.021","article-title":"Pivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCC","volume":"72","author":"Sekulic","year":"2015","journal-title":"J. Am. Acad. Dermatol."},{"issue":"1","key":"10.1016\/j.ctarc.2024.100796_bib0111","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jaad.2013.09.012","article-title":"Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib","volume":"70","author":"Chang","year":"2014","journal-title":"J. Am. Acad. Dermatol."},{"issue":"9","key":"10.1016\/j.ctarc.2024.100796_bib0112","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1007\/s13555-023-00985-1","article-title":"The efficacy of sonidegib in treating locally advanced basal cell carcinoma involving the periocular area","volume":"13","author":"Villani","year":"2023","journal-title":"Dermatol. Ther. (Heidelb)"},{"issue":"6","key":"10.1016\/j.ctarc.2024.100796_bib0113","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/S1470-2045(15)70100-2","article-title":"Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial","volume":"16","author":"Migden","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ctarc.2024.100796_bib0114","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.7573\/dic.2022-1-2","article-title":"Benefit\u2013risk assessment of sonidegib and vismodegib in the treatment of locally advanced basal cell carcinoma","volume":"11","author":"Garc\u00eda Ruiz","year":"2022","journal-title":"Drugs Context."},{"key":"10.1016\/j.ctarc.2024.100796_bib0115","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/6121760","article-title":"A matching-adjusted indirect comparison of sonidegib and vismodegib in advanced basal cell carcinoma","volume":"2017","author":"Odom","year":"2017","journal-title":"J. Skin. Cancer"},{"issue":"9","key":"10.1016\/j.ctarc.2024.100796_bib0116","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1111\/jdv.16230","article-title":"Sonidegib and vismodegib in the treatment of patients with locally advanced basal cell carcinoma: a joint expert opinion","volume":"34","author":"Dummer","year":"2020","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"issue":"Suppl 2","key":"10.1016\/j.ctarc.2024.100796_bib0117","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1007\/s12070-020-02270-5","article-title":"A systematic review article on orbital exenteration: indication, complications and reconstruction methods","volume":"74","author":"Nandi","year":"2022","journal-title":"Indian J. Otolaryngol. Head. Neck. Surg."},{"key":"10.1016\/j.ctarc.2024.100796_bib0118","series-title":"Making Eye Health a Population Health Imperative: Vision for Tomorrow","article-title":"The impact of vision loss","author":"Welp","year":"2016"},{"issue":"3","key":"10.1016\/j.ctarc.2024.100796_bib0119","first-page":"96","article-title":"The impact of visual impairment on quality of life","volume":"5","author":"Khorrami-Nejad","year":"2016","journal-title":"Med. Hypothesis. Discov. Innov. Ophthalmol."},{"issue":"4","key":"10.1016\/j.ctarc.2024.100796_bib0120","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1097\/IOP.0000000000001251","article-title":"Impact of food and drug administration approval of vismodegib on prevalence of orbital exenteration as a necessary surgical treatment for locally advanced periocular basal cell carcinoma","volume":"35","author":"Sagiv","year":"2019","journal-title":"Ophthalmic Plast. Reconstr. Surg."},{"issue":"3","key":"10.1016\/j.ctarc.2024.100796_bib0121","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1684\/ejd.2022.4264","article-title":"Predictive factors of response to vismodegib: a French study of 61 patients with multiple or locally advanced basal cell carcinoma","volume":"32","author":"Juzot","year":"2022","journal-title":"Eur. J. Dermatol."},{"issue":"6","key":"10.1016\/j.ctarc.2024.100796_bib0122","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1159\/000512889","article-title":"Predictive factors of non-response to vismodegib in locally advanced basal-cell carcinoma","volume":"237","author":"Marescassier","year":"2021","journal-title":"Dermatology"},{"issue":"3","key":"10.1016\/j.ctarc.2024.100796_bib0123","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/s41433-022-01982-y","article-title":"The initial rate of tumour response to vismodegib treatment, can predict a complete response outcome for periocular LA-BCC","volume":"37","author":"Tiosano","year":"2023","journal-title":"Eye (Lond)"},{"issue":"1","key":"10.1016\/j.ctarc.2024.100796_bib0124","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1038\/s41598-020-58117-0","article-title":"Gene-related response of basal cell carcinoma to biologic treatment with vismodegib","volume":"10","author":"Sternfeld","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ctarc.2024.100796_bib0125","unstructured":"OCEBM Levels of Evidence Working Group. The Oxford Levels of Evidence 2 [Internet]. Oxford Centre for Evidence-Based Medicine; Available from: https:\/\/www.cebm.ox.ac.uk\/resources\/levels-of-evidence\/ocebm-levels-of-evidence."}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S246829422400008X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S246829422400008X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,11]],"date-time":"2024-11-11T10:01:49Z","timestamp":1731319309000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S246829422400008X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":125,"alternative-id":["S246829422400008X"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2024.100796","relation":{},"ISSN":["2468-2942"],"issn-type":[{"value":"2468-2942","type":"print"}],"subject":[],"published":{"date-parts":[[2024]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Exploring vismodegib: A non-surgical breakthrough in the management of advanced periocular basal cell carcinoma","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2024.100796","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100796"}}